The Epstein-Barr virus (EBV) generally latently infects its target cells with expression of genes conferring resistance to apoptosis. However, the modulation of apoptotic signals during lytic cycle remains poorly understood. We show here that resulting from viral reactivation in the EBV-positive Mutu-I and Akata Burkitt's lymphoma cell lines, a two steps proteasome-dependent downregulation of expression of the proapoptotic protein BimEL occurs. The first drop might be EBV-independent, is ERK 1/2 dependent, and BimEL is phosphorylated on Ser69. A second dramatic drop of the BimEL level observed during the lytic cycle is dependent of EBV-late-gene expression, ERK 1/2 independent, and no further phosphorylation of BimEL on Ser69 occurred. These results demonstrate for the first time, that the lytic cycle contributes to downregulation of BimEL and then could add to protection against apoptosis.
Introduction
Epstein-Barr virus (EBV) is a persistent and widespread human gamma herpesvirus, infecting more than 90% of the adult human population. The virus is associated with the development of lymphomas (Kieff and Rickinson, 2007) . EBV infects latently its target cells and expresses a limited subset of viral genes. EBV infection leads to the immortalization of B-lymphocytes, which is associated with an increase in the resistance of transformed cells to various apoptotic stimuli. Latent infection leads to downregulation of the proapoptotic BH3-only Bcl-2 interacting mediator of cell death, Bim protein (Clybouw et al., 2005 (Clybouw et al., , 2008 which is particularly important in the regulation of apoptosis during B-cell development. Three Bim proteins, BimEL (extra large), BimL (large) and BimS (small) are synthesized from the same transcript.
In vitro, different agents induce the EBV lytic cycle, including phorbol 12-myristate 13-acetate (PMA) (Zur Hausen et al., 1978) , cross-linking of surface immunoglobulin (Takada, 1984) and transforming growth factor beta 1 (TGF-β1) (Fahmi et al., 2000) . The switch from latent to lytic cycle is regulated by two immediate-early proteins ZEBRA (Zta, EB1) and Rta, which are encoded respectively by the EBV BZLF1 and BRLF1 genes (Feederle et al., 2000) leading to expression of early (mainly linked to DNA replication) and late genes that encode principally virion proteins such as Viral Capsid Antigens (VCA). The expression of late genes is abolished by the viral DNA synthesis inhibitor phosphonoacetic acid (PAA). The lytic cycle ultimately leads to the production of the progeny virions (Pattle and Farrell, 2006) . Lytic EBV gene expression might also modify apoptotic process since EBV encodes two lytic anti-apoptotic proteins BHRF1 (Howell et al., 2005) and BALF1 (Altmann and Hammerschmidt, 2005) . It has been noticed that Akata cells very late in EBV replication remained viable by dye exclusion and highly functional (Yuan et al., 2006) . Moreover, Inman et al. (2001) showed that late EBV gene products are required for effective protection of infected B cells from apoptotic death. This led us to investigate the modulation of pro-or anti-apoptotic signalling pathways during EBV lytic cycle.
This work was focused on the regulation of the level of Bim protein during lytic cycle, in cell lines derived from in vivo EBV-infected BL. We report here that during EBV reactivation, a two steps downregulation of expression of the proapoptotic protein BimEL occur. The first drop is ERK 1/2 dependent and might be EBV-independent and a second dramatic drop of the BimEL level is dependent of EBV-lategene expression. Virology 387 (2009) [41] [42] [43] [44] [45] [46] [47] [48] [49] To investigate whether EBV reactivation might directly modulate apoptosis in a B lymphoma cell context, we used two EBV-positive BL-derived cell lines Mutu-I, and Akata as previously described (Touitou et al., 2003) . EBV lytic cycle was achieved by treatment of Mutu-I, and Akata cells respectively with 2 ng/ml of TGF-β1 or 7.5 μg/ml of anti-Ig in a reduced fetal calf serum medium concentration (0.5%). Seventeen hours later, cells were lysed, probed by western blot for ZEBRA and for apoptosis regulating proteins including Bcl-2, Bcl-xL, Bid, Puma, Bax and Bim. As shown in Fig. 1 , TGF-β1, and anti-Ig treatment efficiently induces EBV reactivation in BL cell lines as judged by the induction of ZEBRA protein.
Immunoblot analysis performed on the same cell extracts showed that while the protein levels of Bcl-2, Bcl-xL, Bid, Puma, Bax or the BimL and BimS isoforms varied between cell lines (Mutu-I and Akata), a non consistent difference was observed with the induction of EBV lytic cycle. In contrast, the level of BimEL was reduced dramatically during virus reactivation. Similar results were observed 48 h post induction with TGF-β1, and anti-Ig in Mutu-I, and Akata cells respectively (not shown).
Effect of EBV-late-gene expression on the disappearance of BimEL
In order to determine if late gene expression contributes to the decrease of BimEL expression, Mutu-I and Akata cells were pretreated for 1 h with 100 μM PAA prior to stimulation respectively with TGF-β1 or anti-Ig for various periods of time. BimEL, phospho-ERK 1/2, ERK 1/2, ZEBRA and VCA were assayed by western-blot at different times after induction. As shown in Figs. 2 and 3, two levels of downregulation of BimEL occur after EBV reactivation in Mutu-I or Akata cells. The first step was observed at 4 or 8 h after treatment with TGF-β1 or anti-Ig, (during EBV-early-lytic cycle); this first drop in the BimEL level was similar whether or not the Mutu-I or Akata cells were pretreated with PAA. Thus, this decrease did not depend on the EBV late-lytic cycle. However, in Mutu-I and Akata cells induced respectively by TGF-β1 or anti-Ig, a dramatic second drop of the BimEL level was observed at 16 or 48 h post-treatment. It occurred late in the EBV cycle, when VCA were detected. PAA treatment (which is non-toxic to B cells (not shown)) led to inhibition of the second drop in BimEL expression. Thus, the second decrease in BimEL expression is PAA sensitive, showing that late product(s) of the EBV cycle contributed directly or indirectly to downregulation of BimEL expression.
EBV-negative BL cells BJAB or DG75 treated with anti-Ig (Fig. 4 ) or TGF-β1 respectively (Fig. 5 ) exhibited only one drop of downregulation of BimEL expression whether or not PAA was used. This result suggest that the first decrease of BimEL expression might be EBV independent while the second one is indeed EBV late lytic cycle dependent. We observed that neither TGF-β1 nor anti-Ig treatment affected the viability of the cells used in this study (Fig. 6) .
Twenty nine percent of Mutu-I or 32% of Akata cells, treated respectively with TGF-β1 or anti-Ig, express VCA proteins (Table 1) . The cells labelled with VCA antibodies were negative for Bim expression and we never observed VCA staining in Bim positive cells (data not shown). Fig. 1 . Levels of ZEBRA, Bcl-2, Bcl-xL, Bid, Bim (EL, L and S), Bax and Puma expression in Mutu-I and Akata cells upon EBV reactivation. Cells were incubated in the absence or presence of TGF-β1 (2 ng/ml) or anti-Ig (7.5 μg/ml). The expression of the immediate early EBV protein ZEBRA was analyzed by western blotting 17 h later, using the specific monoclonal antibody Z125. The membrane was then reprobed separately with a panel of specific antibodies directed against Bcl-2, Bcl-xL, Bid, Bim, Bax, Puma and tubulin (loading control). 
Effect of the phosphorylation of the ERK 1/2 MAPkinase on BimEL expression
It was reported that BimEL degradation depends on its phosphorylation by ERK 1/2 MAPKinase in different types of cells including BL cells (Ley et al., 2003; Luciano et al., 2003) . We checked whether this pathway could be involved in regulation of BimEL level in Mutu-I, and Akata cells upon TGF-β1, or anti-Ig treatments. We induced EBV reactivation in these cell lines using the indicated EBV inducer agents either with or without pretreatment by ERK 1/2 MAPKinase inhibitor U0126 (50 μM) and BimEL protein expression was investigated by western blot. As shown in Fig. 7 , inhibition of the ERK 1/2 MAPKinase pathway by U0126 led to a restoration of the initial level of BimEL in Mutu-I and Akata cells. Thus, the activated ERK 1/2 MAPKinase pathway plays a crucial role in regulating BimEL expression. However, as ERK 1/2 is required for ZEBRA expression, and consequently for lategene expression, treatment with U0126 will lead to inhibition of all the events subsequent to ZEBRA expression, including the second drop in BimEL level, explaining why the use of U0126 restored the initial level of BimEL. Phosphorylation of ERK 1/2 was not affected by PAA (Figs. 2  and 3 ), suggesting that the second drop in the BimEL protein did not require an increase in the phosphorylation level of ERK 1/2 proteins.
Phosphorylation of Ser69 of the BimEL protein does not modulate the drop of BimEL level induced by EBV-late-gene expression
It was shown that BimEL, when phosphorylated on Ser69 by ERK 1/2, is rapidly degraded via the proteasome pathway (Luciano et At the indicated time, cells were harvested, washed, lysed; extracts were analyzed by western blotting against BimEL, phospho-ERK 1/2, ERK 1/2, and tubulin (loading control) antibody binding was detected by enhanced-chemiluminescence. Images were captured using a DDC camera (LAS-1000; Fuji system). (B) The signal was quantified with the ImageJ software. The medium and the standard deviation, calculated from two independent experiments, are represented. al., 2003). Phosphorylation of Bim on its Ser69 was assayed by western-blot using specific antibodies in Mutu-I and Akata cells pretreated or not with MG262 a specific proteasome inhibitor, and then treated or not with TGF-β1 or anti-Ig respectively. The EBVnegative cells DG75 and BJAB cells were also treated with MG262 prior to incubation with TGF-β1 or anti-Ig. The results presented in Fig. 8 , showed that Bim phosphorylation resulted from TGF-β1 as well as anti-Ig treatments in EBV-positive as well as in EBVnegative cells. EBV-late-gene expression did not change the level of Bim phosphorylated at residue Ser69. Moreover, when Mutu-I or Akata cells were pretreated with both PAA and MG262, and then induced respectively by TGF-β1 or anti-Ig, the level for phosphoBimEL Ser69 remained unchanged (Fig. 9) . These results suggested that the mechanism(s) involved for the second drop of BimEL expression did not depend on phosphorylation of BimEL on Ser69 by ERK 1/2.
Effect of the proteasome inhibitor on BimEL expression
We investigated the possible mechanism underlying the effect of EBV reactivation on the expression of BimEL. As cited above, ERK 1/2-mediated phosphorylated BimEL has been shown to be degraded by the proteasome pathway (Luciano et al., 2003; Clybouw et al., 2005) . The effect of MG262 on BimEL level was examined upon stimulation by TGF-β1 or anti-Ig. Mutu-I, and Akata cells were incubated (or not) with MG262 (250 nM) for 1 h prior to stimulation with the indicated EBV-inducer agent. This treatment did not affect cell viability (Fig. 10) . BimEL expression was then examined, in cell extracts at 48 h post-treatment. Whereas, MG262 alone had no effect, simultaneous treatment of Mutu-I or Akata cells with both TGF-β1 or anti-Ig respectively, and MG262 led to a restoration of BimEL levels to that seen in the absence of TGF-β1 or anti-Ig (Fig. 7) . This result suggests that the two drops in the level of BimEL expression depended on its degradation by the proteasome.
The decrease of the BimEL level is due to a post-transcriptional mechanism
Semi-quantitative reverse transcription-PCR (RT-PCR) analysis was performed to determine if this observed downregulation of BimEL expression resulted from a modulation of the transcript level. While the signal obtained when the cDNA encoding the ZEBRA protein showed a marked amplification after EBV reactivation, the amplification products corresponding to BimEL were similar in both uninduced and induced EBV-positive BL cells (Fig. 11) suggesting that the lower levels of BimEL protein observed upon EBV reactivation were not due to a decrease of the steady state of RNA level.
Discussion
EBV contributes to the development of B-cell malignancies. Several factors encoded and/or regulated by the virus contribute to transformation. Downregulation of the proapoptotic Bim protein is a critical regulator of B cell survival and reduced expression is a major determinant of lymphoproliferation. Clybouw et al. (2005 Clybouw et al. ( , 2008 showed that latent EBV-infection of BL cells led to downregulation of BimEL expression through proteasomal degradation. This event was dependent of activation of the ERK 1/2 MAPK pathway. We demonstrate in the present study that regulation of the level of BimEL protein not only occur through in vitro EBV infection of BL cells but also during viral reactivation induced in BL cell lines derived from in vivo EBV-infected tumours. Our data show that EBV reactivation was associated with dramatic decrease of BimEL in Mutu-I, and Akata cells, whereas, the amounts of Bcl-2, Bcl-xL, Bid, Puma, Bax, Bim L and S remained constant within a given cell line. As schematized in Fig. 12 , we demonstrated that a two steps downregulation of expression of the proapoptotic protein BimEL occurred during EBV reactivation in BL cell lines, through the proteasome pathway. The first drop, taking place during the early gene expression, was dependent on ERK 1/2 phosphorylation, and might be EBV-independent because (i) virus reactivation can be dissociated from this first reduction of BimEL level, since treatment with MG262 proteasome inhibitor did not reduce ZEBRA-induced expression (Fig. 7) and (ii) a single step of decrease in BimEL level was observed in EBV-negative BL treated with TGF-β1 or anti-Ig (Figs. 4 and 5) . We showed for the first time that, a second dramatic drop of the BimEL level, took place during the late phase of the EBV lytic cycle. This decrease was dependent of EBV replication/EBV-late gene expression. Mechanisms involved in this step were different from the ones involved in those already described because this decrease was ERK 1/ 2 independent since a long term ERK 1/2 phosphorylation did not produce another step in the decrease of BimEL level in EBV-negative cell lines (Figs. 4 and 5) . Moreover, our findings demonstrated for the first time, that the lytic cycle contributes directly or indirectly to downregulation of BimEL. Furthermore our results suggest that although the EBV-late gene-dependent drop in BimEL was proteasome dependent, phosphorylation of Ser69 residue was not crucial for this event.
Several EBV genes, LMP1, BHRF1, BALF1, inhibit apoptosis. It was shown that late EBV lytic cycle was also able to suppress (or at least delay significantly) this process (Inman et al., 2001) . However the cellular molecules modulating this effect were not identified. As Bim is a critical regulator of B cell survival, this event might participate in resistance to death. It was shown that during the lytic cycle EBV may actively block the cell death program and our work provide a mechanism by which EBV lytic gene expression is protective against apoptosis. We propose that downregulation of BimEL, caused directly or indirectly by EBV-late-gene expression, could contribute to induction of BimEL degradation and then to evasion from apoptosis, preventing premature cell death of the host cell during virus particle production.
Materials and methods

Cell culture and reagents
Mutu-I (Gregory et al., 1990) , Akata (Takada et al., 1991) are EBVpositive BL cell lines, BJAB (Klein et al., 1974) and DG75 (Ben-Bassat et al., 1977) are EBV-negative BL cell lines. Cells were grown in RPMI 1640 supplemented with 2 mM glutamine (GIBCO BRL Life Technologies, Grand Island, N.Y.), 100 μg/ml primocin (CAYLA, Toulouse, France), and 10% heat-inactivated fetal calf serum (FCS) (GIBCO BRL Life Technologies, Grand Island, N.Y.). For induction of the EBV lytic cycle, Mutu-I, and Akata cells were stimulated respectively with 2 ng/ml Fig. 7 . Regulation of BimEL expression upon EBV reactivation requires activated ERK 1/2 and proteasome pathways. Mutu-I (A) or Akata (B) cells were incubated 48 h respectively with TGF-β1 (2 ng/ml) or anti-Ig (7.5 μg/ml) either with or without a pretreatment by MG262 (250 nM) or U0126 (50 μM) as indicated. Equal amounts of cell extracts were analyzed by western blotting with antibodies to Bim, phospho-ERK 1/2, ERK 1/2, ZEBRA, and to tubulin (loading control). Antibody binding was detected by enhanced-chemiluminescence. Images were captured using a DDC camera (LAS-1000; Fuji system). (C and D) The signal was quantified with the ImageJ software. The medium and the standard deviation, calculated from two independent experiments, are represented.
of TGF-β1 (R&D Systems Minneapolis, MN, USA) or 7.5 μg/ml of human anti-Ig (Dako, Denmark) in a reduced fetal calf serum medium concentration (0.5%). U0126, MG262 was obtained from Calbiochem (VWR international, France), and PAA was purchased from Sigma (St. Louis, MO, USA). All experiments were repeated at least twice at different times.
Antibodies
The anti-ZEBRA monoclonal antibody Z125 was a generous gift from E. Drouet (Faculté de Pharmacie, Grenoble, France). The antibodies against Bim, Bax, Bcl-2 and Bcl-xL were purchased from Santa-Cruz Biotechnology (Santa-Cruz, CA). The antibodies against Puma, Bid, phospho-Bim (Ser69), ERK 1/2, phospho-ERK 1/2 and tubulin were purchased from Cell Signalling Technology (Beverly, MA, USA). The human anti-VCA antibody was obtained from Ortho Diagnostic System, Inc. (Raritan, New Jersey). The rabbit peroxidaseconjugated IgG, the human peroxidase-conjugated IgG, and the mouse peroxidase-conjugated IgG from Sigma (St. Louis, MO, USA) were used as secondary antibodies. The rabbit monoclonal to Bim (Abcam, Cambridge, UK), the antibodies against VCA (Biotech Laboratories), the donkey anti-rabbit Alexa 488 antibodies (Interchim, Montlucon, France), and the goat anti-mouse Alexa 594 antibodies (Invitrogen, Cergy pontoise, France) were used for fluorescence microscopy analysis.
Immunoblot analysis
Cells were harvested, washed briefly with phosphate-buffered saline, resuspended in a buffer composed of 100 mM Tris-Cl (pH 7.6), 50 mM NaCl, 2 mM EDTA, 0.5% NP-40, phenylmethylsulfonyl fluoride (100 μg/ml), and 1 μg each of leupeptin, pepstatin and aprotinin per ml, and sonicated. Protein concentration was determined using Micro BCA™ Protein Assay Kit from Pierce Biotechnology. An equal amount of protein in loading buffer, heated for 5 min at 100°C and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 10-12% gels were transferred by electroblotting to a nitrocellulose membrane (Schleicher & Schuell, Ecquevilly, France). Membranes were reacted with the indicated primary antibodies using the appropriate dilution as indicated by the manufacturer, followed by treatment with a horseradish peroxidase-conjugated IgG (anti-rabbit, anti-mouse, or anti-human IgG Ab (1:2000-1:4000)) from Sigma (St. Louis, MO, USA). Membranes were visualized with enhancedchemiluminescence (West-pico or femto; Pierce Biotechnology). Images were captured using a DDC camera (LAS-1000; Fuji system).
Immunofluorescence microscopy
Mutu-I and Akata cells were incubated or not with TGF-β1 (2 ng/ ml) or anti-Ig (7.5 μg/ml) respectively for 12 h at 37°C, washed in PBS, plated on glass slides, air dried and fixed in ice-cold acetone for 10 min. Fixed cells were incubated with anti-VCA murine monoclonal antibodies (1/100) or with rabbit anti-Bim monoclonal antibodies (1/100), for 1 h at 37°C. After three 5 min washes in PBS, the cells were incubated with goat anti-mouse immunoglobulin (1/20) or with anti-rabbit IgG (1/500) for 1 h at 37°C. Cells were stained with 4,6-diamidino-2-phenylindole (DAPI) (Sigma, St. Louis, MO, USA). Finally, images were obtained with a Leica LEI-750 system using the Leica LIDA 1.55 software (Acusoft coorporation).
RT-PCR
Total RNA from each uninduced and induced EBV-positive cells lines was isolated using TRIzol reagent and Rnase inhibitors (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. RNA concentration was determined spectrophotometrically. The template cDNA was synthesized by reverse transcription of the total RNA (3 μg) with Moloney murine leukemia virus reverse transcriptase (Promega, Madison, WI) using an oligo (dT)15 primer (Promega). The primers used for PCR amplifications included: 5′-TGATGTAAGTTCTGAGTGTG-3′, 5′-ACGTAAGAGTCGTAAGATAA-3′ for BimEL (Clybouw et al., 2005) , and 5′-TTACACCTGACCCATACCAG-3′, 5′-ACATCTGCTTCAACAGGAGG for ZEBRA (Arbach et al., 2006) . cDNA of HPRT was used as internal control as previously performed (Touitou et al., 2003) .
Determination of cell viability
Cells viability was assessed using LIVE/DEAD reduced biohazard viability/cytotoxicity test, Molecular Probes, Invitrogen (Cergy Fig. 10 . Effects of MG262 and U0126 on cell viability. Viability of Mutu-I and Akata cells following 48 h of the indicated treatments, was assayed using a LIVE/DEAD reduced biohazard viability/cytotoxicity kit (Invitrogen). Staining and analysis were performed as recommended by the manufacturer. Ability of this kit to detect cell death was controlled using a treatment with 0.4 mM of MnCl 2 . Pontoise, France). Staining and analysis were performed as recommended by the manufacturer. Ability of this kit to detect cell death was controlled using a treatment with 0.4 mM of MnCl 2 (El Mchichi et al., 2007) . Cell numbers were determined with a Neubauer-counting chamber.
